findmyKOL
Clinical trialNCT07001748RecruitingPhase 2/PHASE3Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

SponsorECOG-ACRIN Cancer Research GroupEnrollment148Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaPeritoneal Carcinomatosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitaxel chemotherapy directly into your abdominal cavity, in addition to chemotherapy given through a vein in your arm help you live longer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your gastric cancer. The usual approach is defined as care most people get for gastric cancer. If you decide to take part in this study, you will first receive a surgical procedure called a diagnostic laparoscopy. This will help the study doctors learn more about your gastric cancer. Laparoscopy is a minimally invasive surgery for which you will be placed under general anesthesia. Then the surgeon will make small incisions (5mm) on your belly through which a camera and thin instruments are introduced to evaluate the abdomen. This procedure takes about 1 hour to complete. Your study group will be assigned during the surgery. The study groups are described further in the 'What are the study groups?' section below. If you are placed into the study group 1, you will not have an intraperitoneal port (a small device which is placed under the skin and fat of your upper abdomen and a tube that is placed into the abdomen). If you are placed into the study group 2, you will have an intraperitoneal port placed. The reason is that in addition to standard chemotherapy, which is given through a vein in your arm, this port will be used to deliver the medication paclitaxel directly inside your abdomen when you are ready to start study treatment. It is important to know that you will not know your study group until after the surgery is over. This is because information that is learned during the surgery will help determine which study group you are put in. Once you have fully healed from this surgery, you will start study treatment. Depending on which study group you are assigned, you will either receive a standard chemotherapy regimen (the regimen will be chosen by you and your doctor) if you are in study group 1, or paclitaxel through a tube in your belly plus chemotherapy given through a vein in your arm if you are in study group 2. All participants will get treatment for three (3) months after which you will undergo reevaluation. If the disease is under control or responding to treatment, you may continue the assigned treatment until your disease gets worse, the side effects become too severe, or you may be offered a surgical procedure to remove the cancer if the amount of disease is low and can be completely removed as determined by a surgeon. There is a very small chance that during the laparoscopy surgical procedure, the doctor might find something called "intra-abdominal adhesions". These are areas where the stomach has healed previously and created scar tissue. If this scar tissue prevents the surgeon from being able to place a port in the correct area, you would be ineligible to receive the study treatment. If this happens, you may still receive standard of care therapy after your surgery, but you will not be able to continue on the study. If you have more questions about this, you can ask your surgeon or the study team to help. After you finish your study treatment, your doctor or study team will watch you for side effects. They will continue to follow your condition every three (3) months during the first two (2) years, then every six (6) months until year 5. You may be reevaluated with Chest/Abdomen/Pelvis scans every three-six (3-6) months for up to five (5) years if decided by your doctor.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

78 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California, United States

    Maheswari Senthil
    Recruiting
  • Cedars-Sinai Medical Center

    Los Angeles, California, United States

    Alexandra Gangi
    Recruiting
  • Uc Irvine Health/chao Family Comprehensive Cancer Center

    Orange, California, United States

    Maheswari Senthil
    Recruiting
  • Stanford Cancer Institute Palo Alto

    Palo Alto, California, United States

    Byrne Lee
    Recruiting
  • Uchealth University of Colorado Hospital

    Aurora, Colorado, United States

    Sunnie S. Kim
    Recruiting
  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Yale University

    New Haven, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center at Long Ridge

    Stamford, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut, United States

    Raghav Sundar
    Recruiting
  • Uf Health Cancer Institute - Gainesville

    Gainesville, Florida, United States

    Lakshmi Balasubramanian
    Recruiting
  • Emory Saint Joseph'S Hospital

    Atlanta, Georgia, United States

    Seth Concors
    Recruiting
  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

    Seth Concors
    Recruiting
  • Emory University Hospital/winship Cancer Institute

    Atlanta, Georgia, United States

    Seth Concors
    Recruiting
  • Northwestern Medicine Cancer Center Old Irving Park

    Chicago, Illinois, United States

    Brett L. Ecker
    Recruiting
  • Northwestern University

    Chicago, Illinois, United States

    Brett L. Ecker
    Recruiting
  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, United States

    Mecker G. Moller
    Recruiting
  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois, United States

    Brett L. Ecker
    Recruiting
  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois, United States

    Brett L. Ecker
    Recruiting
  • Northwestern Medicine Oak Brook

    Oak Brook, Illinois, United States

    Brett L. Ecker
    Recruiting
  • Memorial Hospital East

    Shiloh, Illinois, United States

    Ramon Jin
    Recruiting
  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois, United States

    Brett L. Ecker
    Recruiting
  • University of Kentucky/markey Cancer Center

    Lexington, Kentucky, United States

    Prakash K. Pandalai
    Recruiting
  • University Medical Center New Orleans

    New Orleans, Louisiana, United States

    Kevin M. Sullivan
    Recruiting
  • University of Maryland/greenebaum Cancer Center

    Baltimore, Maryland, United States

    Jeremy L. Davis
    Recruiting
  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States

    Thomas Enzler
    Recruiting
  • Henry Ford Hospital

    Detroit, Michigan, United States

    Rupen Shah
    Recruiting
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan, United States

    Kathleen Y. Butler
    Recruiting
  • West Michigan Cancer Center

    Kalamazoo, Michigan, United States

    Kathleen Y. Butler
    Recruiting
  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

    Travis E. Grotz
    Recruiting
  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, United States

    Ramon Jin
    Recruiting
  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, United States

    Ramon Jin
    Recruiting
  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, United States

    Ramon Jin
    Recruiting
  • Siteman Cancer Center-South County

    St Louis, Missouri, United States

    Ramon Jin
    Recruiting
38 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intraperitoneal PaclitaxelStandard of Care Chemotherapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Aug 2025
Primary completion
30 May 2030
Completion
30 May 2030
Last update posted
19 Aug 2026
Registered enrollment
148
Registry id
NCT07001748

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.